cardiologist, teacher, seeking 'forever knowledge'; grandfather to Titan, Tucker, Tate, Tenley, AJ, Delaney, Bailey, Brooks, Hadley; PD Cardiology USF/MCOM
Tampa, Florida
Joined September 2013
- Tweets6.1K
- Following1.6K
- Followers1.5K
- Likes9K
Who would think otherwise?
Cardiac electrophysiology procedures must be performed exclusively by trained electrophysiologists: A statement from the Heart Rhythm Society and Heart Rhythm Advocates
heartrhythmjournal.com/artic…
1000%. Town's character and cognition animate and amplify his game to make a champion
You, @SrihariNaiduMD, bring this definition of a "pro" to cardiology arenas/stadiums and make the win about our patients and our colleagues. "The team, the team, the team" - Bo Schembechler
Listen to @KarlTowns here.
This is what leadership is about. As I reflect on my own small contributions in @SCAI, @NYSCACC, shock, ELM, HCM or whatever I also feel it’s most important to just make an impact.
To patients. To your loved ones. To our department. To colleagues. And as a leader, to the field.
Make a difference. But the difference is what’s important. The impact. Not the name.
Doesn’t matter who does it as long as everyone wins. Which is why I’m equally proud of our SHOCK document even though I’m not at #AHA26 for its unveiling. The credit goes to all of us.
Sometimes we need people to start things though. And for the most part that sums up my career.
For most, early career is often “me”. That stage is needed of course. But late career must always be “we”.
@XavierPrida @CASivaram1 @AnkurKalraMD @mirvatalasnag @djc795 @purviparwani @JamalRanaMD @TommyBeer @nyknicks
xavier prida retweeted
STREAM makes a noninferiority claim that its own data undercut: Stopping statins increased heart attacks and strokes, yet the trial was called “noninferior”. Prof #JamesStein18 had not planned to comment on the @AHAScience Sessions this year. But then he read STREAM, an open-label noninferiority trial built on assumptions he finds hard to justify, and he could not let it pass. Its conclusion already is being generalized beyond what the data support. We really need to do better. jamesstein18.substack.com/p/…
xavier prida retweeted
New trial of semaglutide: Once-weekly SC administration of 2.4 mg semaglutide reduced PAWP at rest and during exercise at 52 weeks in patients with obesity-related HFpEF, demonstrating favorable hemodynamic improvement.
Download slides here: clinicaltrialresults.org/wp-…
The origin of the word "mesmerize".
aamc.org/learn-network/learn…
xavier prida retweeted
Individualize stopping statins might have been a reasonable option prior to this trial. Following this trial, it is not!
Nothing compares to the expression of intent as to the design of this and all documents of its kind. Of clinicians' synthesis of the evidence, by clinicians, for clinicians, and of supreme importance to their patients.
Listen to @SrihariNaiduMD and then read the document.
Thanks @CardioBusiness for interviewing me on behalf of the writing group. Tried to summarize the key points of the update.
@SCAI @agtruesdell @davebaran @GiorgioMedranda @Pooh_Velagapudi @Allison_Dupont @djc795 @DNFeldmanMD @tristonsmithmd @JDawnAbbott1 @JCigarroaMD @herbaronowMD @DrMarthaGulati @ChetRihal @nymedcollege @AnkurKalraMD @DLBHATTMD @mirvatalasnag @EllauziRama @purviparwani @JamalRanaMD @dlubarskymd @IvorDouglasMD @larrysdeanmd @HadleyWilsonMD @DrJMarine @drmalissawood @manesh_patelMD @seanvandiepen @thiele_holger @benhibbertMDPhD @adityadoc1 @IvanHansonMD @CheverePhD @PeteMLutz @ladyheart_md @HritvikJain @AHAScience @mmamas1973 @MichaelMegalyMD @MCoylewright @vbluml @Carlos_DavilaMD @escardio @alaide_chief @HarisPatail @ImranAziz96 @KTamirisaMD @iamritu
cardiovascularbusiness.com/t…
This is on point, as I enter a 5th decade of practice.
"Not as good as I once was, but on occasion as good I once as I ever was."
They Are So Young jamanetwork.com/journals/jam…
xavier prida retweeted
Reading good books teaches you things that scrolling never will.
— Patience to follow a long argument
— Concentration to study difficult ideas
— Vocabulary to express yourself clearly
— Historical knowledge to understand the present
— Judgment to recognize weak arguments
— Curiosity to keep learning
None of these skills develops overnight.
They come from spending years reading, thinking, and returning to books that challenge you.
There is no shortcut to becoming well-read.
xavier prida retweeted
Thanks @CardioBusiness for interviewing me on behalf of the writing group. Tried to summarize the key points of the update.
@SCAI @agtruesdell @davebaran @GiorgioMedranda @Pooh_Velagapudi @Allison_Dupont @djc795 @DNFeldmanMD @tristonsmithmd @JDawnAbbott1 @JCigarroaMD @herbaronowMD @DrMarthaGulati @ChetRihal @nymedcollege @AnkurKalraMD @DLBHATTMD @mirvatalasnag @EllauziRama @purviparwani @JamalRanaMD @dlubarskymd @IvorDouglasMD @larrysdeanmd @HadleyWilsonMD @DrJMarine @drmalissawood @manesh_patelMD @seanvandiepen @thiele_holger @benhibbertMDPhD @adityadoc1 @IvanHansonMD @CheverePhD @PeteMLutz @ladyheart_md @HritvikJain @AHAScience @mmamas1973 @MichaelMegalyMD @MCoylewright @vbluml @Carlos_DavilaMD @escardio @alaide_chief @HarisPatail @ImranAziz96 @KTamirisaMD @iamritu
cardiovascularbusiness.com/t…
xavier prida retweeted
Among the biggest changes in intravenous thrombolysis practice in the past 5 years has been the increased use of tenecteplase over alteplase. Tenecteplase, a slightly modified form of tissue plasminogen activator, has more fibrin specificity and longer half-life than alteplase and therefore can be given more conveniently as a single bolus rather than the one-hour infusion needed for alteplase. In the past decade, tenecteplase has been tested in comparison with alteplase in patients with acute ischemic stroke. Although tenecteplase may result in higher rates of recanalization, trials have shown that clinical outcomes are essentially equivalent between the two drugs — or at least the conclusion can be made that tenecteplase is noninferior to alteplase in terms of benefit and safety. Largely on the basis of these noninferiority results, in 2025, the FDA approved the use of tenecteplase in patients with acute ischemic stroke. Although accurate patient weight is important to establish doses for both alteplase and tenecteplase, the tiered dosing of tenecteplase that was approved by the FDA (seen in table) makes rapid determination of the appropriate dose easier.
Read the Review Article “Intravenous Thrombolysis for Acute Ischemic Stroke — New Directions”: nej.md/4iuL5Lr
ALT A table showing recommended doses of tenecteplase for persons with acute ischemic stroke. The columns are "Body Weight" and "Tenecteplase Dose," which gives values in mg and ml.
xavier prida retweeted
Harvard Professors Leaving for Private Sector Research | Harvard Magazine harvardmagazine.com/2025/01/…
xavier prida retweeted
So happy to see @SpatzErica receive a well-deserved leadership award from @YaleIMed. She leads by making others around her better, by focusing on teams, and by investing in people and ideas. She is simply incredible. @YaleCardiology @JACCJournals
xavier prida retweeted
Hilaire Belloc explains why you need to read old books:
“There is no habit more dangerous to a man's active intellectual life than that of reading only modern books. The contemporary writer is usually not yet judged by time. He writes under the pressure of fashion and opinion. But the old books have survived. They have been tested. They come to us stamped with the approval of generations. To read them is to breathe a larger air.”
Which old book are you immersed in right now?
xavier prida retweeted
Ok the time has come!
This Sunday at #AHA2026 we unveil the 2026 SCAI SHOCK classification update, presented by my co-chair @davebaran on behalf of the writing group & all endorsing societies! Simultaneous publication in @MyJSCAI.
Lots of new updates to provide clarity, granularity, consensus and direction to level-set the field!
Details below ⬇️
@AlexandraLansky @agtruesdell @SCAI @Babar_Basir @vbluml @debdiercks @Allison_Dupont @HenrytTimothy @JasonKatzMD @SandeepNathanMD @mwkrucoff @ShashankSinhaMD @SarasVallabhMD @seanvandiepen @mirvatalasnag @DLBHATTMD @djc795 @TCTMD @CardioBusiness @theheartorg @nymedcollege @ACCinTouch @AHAScience @STS_CTsurgery @SCCMPresident @ISHLT
xavier prida retweeted
I’m honored to be the recipient of the 2027 Dr. Carolyn McCue Award for Woman Cardiologist of the Year @VCU @WomenAs1 @global_wic
vcuhealth.org/news/mirvat-al…
xavier prida retweeted
Bioprosthetic valve dysfunction (BVD), hemodynamic valve dysfunction (HVD), and bioprosthetic valve failure (BVF): they may sound synonymous, but they are not. I tried to clarify the differences.
The discussion also brought back the valve durability clock, which divided the panel. Some argued that it is not a major concern: we intervene earlier because intervention will eventually be necessary anyway. I somewhat disagree. To me, this is a conceptual and, to some extent, an ethical issue, particularly since we are not talking about a demonstrated mortality benefit of early intervention over clinical surveillance. Symptoms will eventually develop, but how soon? Moderate stenosis will eventually progress to severe stenosis, but over what timeframe?
Intervening 1–2 years earlier in a patient whose life expectancy is shorter than the valve’s remaining durability is one thing. Intervening 5–6 years earlier in a patient who is likely to outlive the valve is quite another. In the latter scenario, I believe we should seriously question whether early intervention is preferable to clinical surveillance. Perhaps it is time to revisit the natural history studies of aortic stenosis, which certainly exist, to better understand the time course of progression from, e.g., moderate to severe stenosis, and from an asymptomatic state to the development of symptoms. #TCT2026
